Front Month Nymex RBOB Gasoline Rose 5.50% This Week to Settle at $2.0364 — Data Talk
Front Month Nymex RBOB Gasoline for Oct. delivery gained 10.62 cents per gallon, or 5.50% to $2.0364 this week
--Largest one week gain since the week ending June 21, 2024
--Largest one week percentage gain since the week ending March 15, 2024
--Up for two consecutive weeks
--Up 14.04 cents or 7.41% over the last two weeks
--Largest two week net and percentage gain since the week ending March 22, 2024
--Today it is down 2.36 cents or 1.15%
--Largest one day dollar and percentage decline since Tuesday, Sept. 10, 2024
--Snaps a seven session winning streak
--Off 27.85% from its 52-week high of $2.8223 hit Tuesday, April 16, 2024
--Up 8.90% from its 52-week low of $1.87 hit Tuesday, Sept. 10, 2024
--Down 20.51% from 52 weeks ago
--Off 27.85% from its 2024 settlement high of $2.8223 hit Tuesday, April 16, 2024
--Up 8.90% from its 2024 settlement low of $1.87 hit Tuesday, Sept. 10, 2024
--Off 52.38% from its record high of $4.2762 hit Thursday, June 9, 2022
--Month-to-date it is down 7.93%
--Year-to-date it is down 6.62 cents or 3.15%
All prices are calculated based on the settlement price of the current front month contract.
Source: Dow Jones Market Data
(END) Dow Jones Newswires
September 20, 2024 15:02 ET (19:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk